While AstraZeneca CEO Pascal Soriot's proposed pay package has attracted criticism ahead of the company's annual meeting, a large investor has swooped in to support ...

Even as Novartis rolls ahead with a global restructuring campaign targeting thousands of job cuts, the Swiss drug giant has blueprinted several hundred layoffs in it...

Medicare drug price negotiations under the Inflation Reduction Act are steadily progressing after drugmakers recently submitted their counteroffers to the government...

Fifteen years after gaining its first FDA approval for Fanapt (iloperidone) to treat schizophrenia, Vanda Pharmaceuticals has scored again with the same antipsychoti...

Demand fluctuations have spurred Thermo Fisher Scientific to downsize at the plasmid DNA manufacturing facility the company opened a little less than three years ago...

As April’s National Minority Health Month begins, Johnson & Johnson is picking up the pace in its “race to health equity.” The company announced Wednesday tha...

Grant awarded to support the expansion of Almac’s small molecule API manufacturing plant Almac Sciences, a member of the Almac Group, has been awarde...

With Livmarli sales reaching $142 million during its second full year on the market, Mirum Pharmaceuticals’ rare liver disease treatment is off to a solid start in f...

About a year after launching a prior round of layoffs, Coherus BioSciences is again reducing its head count, this time by 30%. Coherus unveiled the latest job cut...

After a few holdups, Swiss skincare company Galderma is finally going public in a highly anticipated market debut that could make for one of Europe’s largest listing...